Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL25324035 | 0.91 | CHRNA7 (0.49) | CHRNA7SLC6A4HTR2CHTR2BSSTR4 | |
| SCHEMBL25944647 | 0.89 | CHRNA7 (0.40) | CHRNA7SLC6A4HTR2CHTR2BSSTR4 | |
| SCHEMBL31071555 | 0.86 | KDM1A (0.46) | CHRNA7SLC6A4HTR2CSCN8ASCN10A | |
| SCHEMBL23105273 | 0.86 | SSTR4 (0.46) | CHRNA7SLC6A4HTR2CHTR2BSSTR4 | |
| SCHEMBL23105272 | 0.86 | SSTR4 (0.46) | CHRNA7SLC6A4HTR2CHTR2BSSTR4 | |
| SCHEMBL21984967 | 0.84 | MRGPRX4 (0.47) | SLC6A4HTR2CHTR2B | |
| SCHEMBL19833874 | 0.83 | CHRNA7 (0.42) | CHRNA7SSTR4SCN8A | |
| SCHEMBL2561940 | 0.81 | SLC6A4 (0.44) | SLC6A4HTR2CHTR2BSSTR4CHRNB2 | |
| Hydrochloric Acid SCHEMBL1230448 | 0.80 | SLC6A4 (0.43) | SLC6A4HTR2CHTR2BSSTR4CHRNB2 | |
| Trifluoroacetic Acid SCHEMBL23149370 | 0.79 | SSTR4 (0.47) | CHRNA7SLC6A4HTR2CHTR2BSSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | CHRNA7 703/4885SLC6A4 609/4885HTR2C 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.